OCT completed patient enrollment in a phase I trial

This is a multicenter, open-label cohort phase I clinical study in patients with chronic myeloid leukemia.

The study is aimed to assess the safety, tolerability, toxicity and pharmacokinetics of the investigational drug. The study is designed to determine the maximum tolerated dose.

The study participants include male and female patients, over 18 years old. The planned duration of treatment is not limited by the protocol: in case of good tolerability of the investigational drug, treatment period will continue while the response to therapy exists which is estimated at 12 months.

OCT will be responsible for the full scope of services within the study.

Back to the list